BSESyschem India LtdHighPositive
Announced Mon, 5 Jan · 11:36 IST

Pursuant to regulation 30 of SEBI (LODR) Regulation, 2015, Intimation for the commencement of commercial Production for the new and existing Production Unit.

Business Updates View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Syschem India has started commercial production at two units at its Panchkula, Haryana facility from 5th January 2026. The new 'Ganga' unit will manufacture Cloxacillin Sodium, Dicloxacillin Sodium and Flucloxacillin Sodium with an installed capacity of 600 MT per annum. The expanded 'SARU' unit will manufacture Amoxicillin with an additional installed capacity of 1,200 MT per annum. The company says this follows the board approval from September 2025 and there is no material deviation from the original plan. Together, the new and expanded units add 1,800 MT of annual manufacturing capacity, which the company expects to enhance overall production capacity, improve operational efficiency, and meet growing market demand.

Likely market impact

This is a positive operational milestone that expands the company's manufacturing capacity and could support future revenue growth, though it remains to be seen how quickly the new capacity is utilised and monetised.